Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, 2-Injection, 52-Week Study to Evaluate the Efficacy and Safety of Intra-articular Injections of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, 2-Injection, 52-Week Study to Evaluate the Efficacy and Safety of Intra-articular Injections of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Acronyms VICTORY-2
  • Sponsors Centrexion Therapeutics

    • Most Recent Events

    • 15 Nov 2023 Results of an analysis from combined data set from two studies (CNTX4975i-OA301 and CNTX4975i-OA304) reporting primary time point at week 12 with the numeric pain rating scale (Primary OA-301) between NPRS and WOMAC-A (Primary OA-304) presented at the ACR Convergence 2023
    • 15 Nov 2023 Primary endpoint has not been met. (The Western Ontario and McMaster Universities Osteoarthritis Index Subscale A (pain) week 12), as per Results presented at the ACR Convergence 2023
    • 15 Nov 2023 Results presented at the ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top